Stocks · News reference
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.
Read original at benzingaRapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.96) by 23.96 percent. This is a 58.67 percent decrease over losses of $(0.75) per
Read original at benzingaFiled: 2026-08-05 AccNo: 0001193125-26-333853 Size: 464 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar